论文部分内容阅读
全球范围内丙型肝炎病毒(hepatitis C virus,HCV)感染率约为3%,感染后的慢转率可达50%~85%。抗-HCV(+)者在接受单克隆抗体、肿瘤坏死因子抑制剂、糖皮质激素或其他免疫抑制剂治疗时可能会发生HCV再激活,从而不但可能导致肝衰竭,而且将延误或中断肿瘤、自身免疫性疾病等的及时治疗。这类患者发生HCV再激活时,不适宜应用干扰素联合利巴韦林抗HCV治疗,直接抗病毒药物已成为最佳且惟一选择。
The worldwide hepatitis C virus (HCV) infection rate is about 3%, after infection, the slow rate of up to 50% to 85%. Anti-HCV (+) may undergo HCV reactivation when treated with monoclonal antibodies, tumor necrosis factor inhibitors, glucocorticoids, or other immunosuppressive agents that may not only lead to liver failure but will delay or interrupt the tumor, Autoimmune diseases such as timely treatment. Interferon and ribavirin are not suitable for HCV reactivation in these patients. Direct antiviral drugs have become the best and only choice.